CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION

PROGRESS ON PHASE III CLINICAL TRIAL OF RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR)

This announcement is made by CanSino Biologics Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated September 2, 2020, in relation to, among other things, the phase III clinical trial of its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "**Ad5-nCoV**"). The Company has completed case accrual for the interim analysis of the phase III clinical trial of Ad5-nCoV and the data of these cases has been submitted to the Independent Data Monitoring Committee (the "**IDMC**") for analysis and recommendation.

The Company is pleased to announce that it has been informed by the IDMC that Ad5-nCoV has successfully met its pre-specified primary safety and efficacy criteria at this interim analysis. There were no vaccine related serious adverse events ("**SAE**") and therefore the Company could continue to advance the phase III clinical trial of Ad5-nCoV. As at the date of this announcement, the Company remains blinded to whether the participants involved in the trial received vaccine or placebo. Further announcement(s) regarding the details and developments of the phase III clinical trial of Ad5-nCoV will be made by the Company as and when appropriate.

Information about the phase III clinical trial of Ad5-nCoV

This phase III clinical trial of Ad5-nCoV is a global multicenter, randomized, double-blind, placebo-controlled, adaptive designed phase III clinical trial to evaluate the efficacy, safety and immunogenicity of Ad5-nCoV in adults 18 years of age and older. All participants received a single dose of either Ad5-nCoV or a placebo vaccine on Day 0 and will be followed to monitor vaccine candidate efficacy and incidence of SAE for a duration of 52 weeks. The primary efficacy objective is the efficacy of Ad5-nCoV in preventing virologically confirmed (PCR positive) symptomatic COVID-19 disease, regardless of severity, occurring 28 days to 52 weeks after vaccination. COVID-19 disease rates in Ad5-nCoV group will be compared with COVID-19 rates in the control group. The primary safety objective is to evaluate the incidence of SAE and medically attended adverse events within 52 weeks after vaccination in all participants.

The phase III clinical trial of Ad5-nCoV has vaccinated more than 40,000 volunteers in 78 clinical trial sites across five countries over three continents, which is led by global principal investigator ("**PI**"), global co-PI and country co-PI from seven countries, and strictly complies with high ethical standards and rigorous scientific principles.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The safety and efficacy of Ad5-nCoV is subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or market Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 1, 2021

As at the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.